MediWound

A biopharmaceutical company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair.

Health Tech & Life Sciences
public
Public Yavne, Israel Founded 2000
Last updated 2026-11-05
Total raised
$407.5M
Last: Public Offering 2026-11
Stage
Public
Founded
2000
Headcount
121
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences

About

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for non-surgical tissue repair. Its solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering a safer and more effective alternative to traditional methods. With robust in-house research, development, and manufacturing capabilities, the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient outcomes, and reduce healthcare costs by eliminating the need for surgical interventions. MediWound’s flagship product, NexoBrid, is an FDA, EMA and PMDA approved orphan designated biologic, currently in use worldwide for treating severe burns. Building on its proprietary enzymatic technology, MediWound is advancing EscharEx, a promising Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

Funding history · 14 rounds · $407.5M total

14 events/rounds · $407.5M Total Funding: $20.0M in Private Equity, $380.7M in Public Equity, $6.8M in Debt
Nov 2026
Public Offering $15.0M EDGAR filing SEC-EDGAR 424B5
Sep 2025
Public Offering $30.0M EDGAR filing SEC-EDGAR 424B5
Mar 2025
Public Offering $125.0M EDGAR filing SEC-EDGAR 424B3
Sep 2024
Public Offering $25.0M EDGAR filing SEC-EDGAR 424B3
Apr 2023
Public Offering $35.5M EDGAR filing SEC-EDGAR 424B3
Sep 2022
Public Offering $13.3M EDGAR filing SEC-EDGAR 424B5
Mar 2022
Public Offering $10.0M EDGAR filing SEC-EDGAR 424B5
Feb 2020
Public Offering $15.0M EDGAR filing SEC-EDGAR 424B5
Sep 2017
Public Offering $22.0M EDGAR filing SEC-EDGAR 424B5
Mar 2014
Public Offering $70.0M EDGAR filing SEC-EDGAR 424B4
Jun 2013
Public Offering $20.0M mtec-sc.org
★ Arte★ Leor Rosenberg★ Israeli institutions★ Mölnlycke Health Care★ financial institutions★ Clal Biotechnology Industries★ several Israeli investment institutions★ Migdal Insurance and Financial Holdings Ltd.MTECPoint72Sol J. BarerYair Schindel1 angel investorClal Biotechnologyother current shareholdersother financial institutionsSeven global financial institutionsEuropean Innovation Council (EIC) Accelerator programHarel Insurance Investments and Financial Services Ltd.
Dec 2012
Convertible Debt $6.8M calcalist.co.il
★ Teva Pharmaceutical Industries Ltd.
Nov 2010
Secondary Round Undisclosed calcalist.co.il ↗
★ Teva Pharmaceutical Industries Ltd.★ PolyHeal Ltd.Polyheal

Offices

Yavne, Israel · HQ / main office

Q&A

What is MediWound's primary focus?
MediWound is a biopharmaceutical company specializing in developing and commercializing enzymatic therapies for non-surgical tissue repair, particularly for wound and burn care.
When was MediWound founded and where is its headquarters located?
MediWound was founded in January 2000 and is headquartered in Yavne, Israel.
What is MediWound's flagship product?
MediWound's flagship product is NexoBrid, an FDA, EMA, and PMDA-approved orphan-designated biologic used worldwide for treating severe burns.
What is MediWound's current pipeline drug?
MediWound is advancing EscharEx, a Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
How much funding has MediWound raised in total?
MediWound has raised a total of $405,473,265.61 through various funding rounds.
When was MediWound's most recent funding round and what type was it?
MediWound's most recent funding round was a Public Offering in November 2026, raising $15,000,000.
Who are the founders of MediWound?
The founders of MediWound are Lior Rosenberg and Marian Gorecki.
Who is the current CEO of MediWound?
Ofer Gonen is the Chief Executive Officer of MediWound.

Team · 17

Lior Rosenberg
Founder · Medical Director
LinkedIn ↗
Marian Gorecki
Founder · founders
Ofer Gonen
Chief Executive Officer
LinkedIn ↗
Hani Luxenburg
Chief Financial Officer
LinkedIn ↗
Shmulik Hess
Chief Operating & Commercial Officer
LinkedIn ↗
Ety Klinger
Chief Medical Officer
LinkedIn ↗
Yaron Meyer
EVP, General Counsel & Corporate Secretary
LinkedIn ↗
Barry J. Wolfenson
EVP Strategy & Corporate Development
LinkedIn ↗
Robert J. Snyder
SVP, Global Medical Affairs
LinkedIn ↗
Aya Ben Yaakov
VP Clinical & Regulatory Affairs
LinkedIn ↗
Alexandra (Sandra) Teplitsky
VP Quality Assurance
LinkedIn ↗
Liron Gal
VP Manufacturing Science & Technology
LinkedIn ↗
Nachum (Homi) Shamir
Chairman of the Board
LinkedIn ↗
Stephen T. Wills
Board Member
LinkedIn ↗
Dr. Vickie R. Driver
Board Member
LinkedIn ↗
David Fox
Board Member
LinkedIn ↗
Shmuel (Milky) Rubinstein
Board Member
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
Manufacturing

Highlights

Patents

Tags

tissue-regenerationdermatologyburnsbiotechnologytopical-treatmentpatientspharma-companiespharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitemediwound.com
LinkedInlinkedin.com/company/1644054
Wikidatawikidata.org/wiki/Q43896231

Identifiers & details

Legal nameMediWound Ltd.
Founded2000-1
Employees (exact)121
Wikidata QIDQ43896231

Radar intelligence

Patents

EPO14

Publications (Crossref)

Works5

Web history (Wayback)

Domainmediwound.com

Wikidata

QIDQ43896231

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)512894940
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated2000-01-27
Purposeלעסוק בסוגי עיסוק שפורטו בתקנון
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2022
Active charges / liens0
Registry events1 — charge (1)
Registered addressהירקון 42 יבנה

Recent registry events

DateEvent
2026-08-12עדכון שעבוד